pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·1h ago·1 min read
save

Medicare postpones controversial rule that bars hospitals from using third-party remote patient monitoring services

Nov 5, 2026·read at STAT ↗RegulatoryNegative

Medicare announced it will finalize a proposal that delays an update to its remote patient monitoring (RPM) rule, despite strong opposition.

The rule would prohibit hospitals and other providers from contracting third-party companies to deliver RPM services, effectively limiting the use of external vendors for patient monitoring.

Industry observers note the decision could slow adoption of RPM technologies and affect business models that rely on third-party services, while advocates argue it protects patient data and ensures provider accountability.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Medicare delays controversial RPM rule update”

read at STAT ↗
477 words · retrieved 22m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ProMIS Neurosciences Inc.
topics
Psychiatry & CNS2Oncology

related stories

  • Oct 8Chutes & Ladders—Vir looks to Liu to lead late-stage pushFierce Biotech
  • May 6Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myelomaonclive
  • May 6Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Canceronclive
  • May 6Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphomaonclive
  • May 6Dr Sznol on Biomarkers of Response in Metastatic Melanomaonclive